Figure 6.

Macrophages are reprogrammed toward a predominantly M1-like phenotype through IRF1. (A,B) qRT-PCR analysis of Nos2, Il-12b, and Tnfα (A) or Mrc1 and Arg1 (B) mRNA expression in BMDMs activated with TLR7 agonist R848 for 6 h in the presence or absence of different MEK1/2 inhibitors. Data are means ± SD pooled from 4 experiments. (C–E) Flow cytometry analysis of MHC II (C), CD80 and CD163 (D), and CD64 (E) surface expression on BMDMs stimulated with R848 for 24 h in the presence or absence of MEKi-U. Data with means ± SD are from 4 independent experiments. (F,G) qRT-PCR analysis of the indicated mRNAs expressed in WT and Stat1^−/− (F) or Irf1^−/− (G) BMDMs activated with TLR7 agonist R848 for 6 h in the presence or absence of different MEK1/2 inhibitors. Data are means± SD pooled from 4 experiments. (H) Flow cytometry analysis of MHC II⁺ CD163⁻ M1 and MHC II⁻ CD163⁺ M2 phenotypes in WT and Irf1^−/−mice BMDM stimulated with R848 for 24 h in the presence or absence of MEKi-U. Contour plots are representative of 4 independent experiments. Quantified% positive data with means ± SD are from all experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 by one-way ANOVA (A,B) with Bonferroni's correction (F,G) or unpaired Welch's t-test (C–H).